| Literature DB >> 29611393 |
Bin Li1, Yao Chen1, Zhiyun Wu1, Zhichang Zhao2, Juan Wu1, Yingping Cao3.
Abstract
Entities:
Mesh:
Substances:
Year: 2018 PMID: 29611393 PMCID: PMC5895872 DOI: 10.3343/alm.2018.38.4.384
Source DB: PubMed Journal: Ann Lab Med ISSN: 2234-3806 Impact factor: 3.464
Distribution of PMQR genes in E. coli phylogenetic groups and the corresponding fluoroquinolone minimal inhibitory concentration (MIC) ranges
| PMQR genes | N | Phylogenetic group (N, %) | Ciprofloxacin (μg/mL) | Levofloxacin (μg/mL) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B1 | B2 | D | MIC range | MIC50 | MIC90 | MIC range | MIC50 | MIC90 | ||
| 38 | 25 (65.8) | 9 (23.7) | 4 (10.5) | 0 | 1–64 | 4 | 32 | 1–128 | 4 | 32 | |
| 33 | 16 (48.5) | 6 (18.2) | 3 (9.1) | 8 (24.2) | 1–256 | 32 | 128 | 2–64 | 8 | 32 | |
| 32 | 18 (56.3) | 10 (31.3) | 0 | 4 (12.5) | 1–64 | 8 | 32 | 1–32 | 8 | 16 | |
| 6 | 3 (50) | 3 (50) | 0 | 0 | 1–8 | 2 | 8 | 1–32 | 4 | 32 | |
| 4 | 2 (50) | 2 (50) | 0 | 0 | 8–32 | 16 | 32 | 16–32 | 16 | 32 | |
| 2 | 2 (100) | 0 | 0 | 0 | - | - | - | - | - | - | |
| 2 | 2 (100) | 0 | 0 | 0 | - | - | - | - | - | - | |
| 1 | 0 | 0 | 0 | 1 | - | - | - | - | - | - | |
| 1 | 1 | 0 | 0 | 0 | - | - | - | - | - | - | |
| 1 | 1 | 0 | 0 | 0 | - | - | - | - | - | - | |
| Total | 120 | 70 (58.3) | 30 (25.0) | 7 (5.8) | 13 (16.7) | ||||||
Abbreviations: MIC50, minimum inhibitory concentration required to kill 50% of the microbial population; MIC90, minimum inhibitory concentration required to kill 90% of the microbial population.
Association between antimicrobial susceptibility and β-lactamase genes in PMQR-positive E. coli isolates
| Antimicrobial agents | MIC (μg/mL) | Resistance rate (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total (N=120) | β-lactamase gene-positive strains (N=99) | β-lactamase gene-negative strains (N=21) | ||||||||
| MIC range | MIC50 | MIC90 | S | R | S | R | S | R | ||
| Nalidixic acid | 16–512 | 512 | 512 | 0 | 100 | 0 | 100 | 0 | 100 | - |
| Ciprofloxacin | 0.5–512 | 8 | 64 | 9.2 | 78.3 | 8.1 | 81.8 | 14.3 | 57.1 | 0.407 |
| Levofloxacin | 0.5–256 | 8 | 32 | 10.8 | 66.7 | 10.1 | 71.7 | 14.3 | 42.9 | 0.463 |
| Cefotaxime | 0.125–512 | 0.125 | 128 | 56.7 | 43.3 | 51.5 | 48.5 | 85.7 | 14.3 | 0.004 |
| Gentamicin | 0.125–512 | 2 | 128 | 52.5 | 45.8 | 49.5 | 48.5 | 71.4 | 28.6 | 0.081 |
| Cefepime | 0.125–512 | 0.125 | 8 | 92.5 | 4.2 | 92.9 | 3.0 | 95.2 | 4.8 | 0.555 |
| Amikacin | 0.125–512 | 2 | 2 | 97.5 | 2.5 | 97.0 | 3.0 | 100 | 0 | 1.000 |
| Imipenem | 0.125–4 | 0.25 | 0.5 | 100 | 0 | 100 | 0 | 100 | 0 | - |
*Statistical significance (P) was calculated using the Pearson Chi-square test in terms of the number of resistant strains and susceptible strains in the β-lactamase gene-positive and β-lactamase gene-negative groups. Intermediate isolates were considered non-susceptible isolates.
Abbreviations: S, susceptible; R, resistant; MIC, minimum inhibitory concentration; MIC50, minimum inhibitory concentration required to kill 50% of the microbial population; MIC90, minimum inhibitory concentration required to kill 90% of the microbial population.